China-headquartered Innovent Bio has announced that the fourth Phase III trial DREAMS-3 of mazdutide, a glucagon-like peptide ...

USA-based Intellia Therapeutics has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase ...

US biopharma Organon has endured a tough time in the stock market and faces having to repair its reputation following a ...

Merck & Co, known as MSD outside of the USA and Canada, and Japan’s Eisai today announced that the Phase III LITESPARK-011 ...

Shares of US biotech major Regeneron Pharmaceuticals were up 8.7% at $636.00 in mid-morning trading, after it announced ...

Russia is facing a sharp growth of drug price these days due to a record inflation and the ever-deteriorating business ...

UK pharma major GSK and US clinical-stage biotech Empirico, with leading capabilities in human genetics-driven target ...

US biopharma company Incyte has announced new data from the Phase IIIb TRuE-AD4 study evaluating the efficacy and safety of ...

USA-based CNS specialist MapLight Therapeutics successfully made its public debut on Sunday evening, raising more than $250 ...

UK pharma major GSK and private French biotech Syndivia company, which is focused on next-generation antibody-drug conjugate ...

Denmark-based Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for ...

UK pharma major AstraZeneca’s rare disease unit Alexion today revealed that Koselugo (selumetinib), its oral, selective MEK ...